Published in Joint Bone Spine on May 01, 2002
Shockwave therapy under ultrasonographic guidance in rotator cuff calcific tendinitis. Joint Bone Spine (2001) 1.39
NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest (2004) 5.06
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood (2008) 3.03
Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J Biol Chem (2003) 1.91
IKK mediates ischemia-induced neuronal death. Nat Med (2005) 1.83
NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett (2010) 1.67
Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst (2006) 1.63
NF-kappaB controls the global pro-inflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program. Nucleic Acids Res (2005) 1.57
TNFalpha promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB signaling pathway. Bone (2009) 1.55
Extracorporeal shock wave therapy for the treatment of chronic calcifying tendonitis of the rotator cuff: a randomized controlled trial. JAMA (2003) 1.42
Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol (2010) 1.41
Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res (2010) 1.40
Hepatic activation of IKK/NFκB signaling induces liver fibrosis via macrophage-mediated chronic inflammation. Hepatology (2012) 1.40
[The effectiveness of radiation treatment in comparison with extracorporeal shockwave therapy (ESWT) in supraspinatus tendon syndrome]. Strahlenther Onkol (2002) 1.40
Epithelial-mesenchymal transition: NF-kappaB takes center stage. Cell Cycle (2004) 1.38
KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma. Blood (2010) 1.38
Deficiency of innate and acquired immunity caused by an IKBKB mutation. N Engl J Med (2013) 1.37
Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood (2002) 1.32
FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood (2012) 1.31
Reduction of marginal zone B cells in CD22-deficient mice. Eur J Immunol (2002) 1.31
The Yaa mutation promoting murine lupus causes defective development of marginal zone B cells. J Immunol (2003) 1.25
Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood (2005) 1.24
Constitutive IKK2 activation in acinar cells is sufficient to induce pancreatitis in vivo. J Clin Invest (2007) 1.24
Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood (2004) 1.23
Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells. J Biol Chem (2002) 1.21
Identification of novel Myc target genes with a potential role in lymphomagenesis. Nucleic Acids Res (2004) 1.20
Cardiomyocyte-specific IκB kinase (IKK)/NF-κB activation induces reversible inflammatory cardiomyopathy and heart failure. Proc Natl Acad Sci U S A (2012) 1.17
Iodoxolone-based hypervalent iodine reagents. Org Lett (2009) 1.15
Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol (2010) 1.14
A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Hum Mol Genet (2002) 1.14
Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol (2004) 1.12
The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis. Blood (2009) 1.11
The IKK-2/Ikappa Balpha /NF-kappa B pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts. A critical link to dermatitis in Ikappa Balpha -deficient mice. J Biol Chem (2001) 1.11
C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. Int J Cancer (2007) 1.11
Post-transcriptional regulatory element boosts baculovirus-mediated gene expression in vertebrate cells. J Biotechnol (2007) 1.10
Advanced organic synthesis using microreactor technology. Org Biomol Chem (2006) 1.10
BOB.1/OBF.1 controls the balance of TH1 and TH2 immune responses. EMBO J (2007) 1.10
FoxO3 induces reversible cardiac atrophy and autophagy in a transgenic mouse model. Cardiovasc Res (2011) 1.09
IκB kinase/nuclear factor κB-dependent insulin-like growth factor 2 (Igf2) expression regulates synapse formation and spine maturation via Igf2 receptor signaling. J Neurosci (2012) 1.08
Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res (2009) 1.06
Iodine monochloride-amine complexes: an experimental and computational approach to new chiral electrophiles. Chemistry (2005) 1.06
Reversible lymphomagenesis in conditionally c-MYC expressing mice. Int J Cancer (2004) 1.06
Reagent-controlled stereoselective iodolactonizations. Org Lett (2002) 1.03
B cell-specific transgenic expression of Bcl2 rescues early B lymphopoiesis but not B cell responses in BOB.1/OBF.1-deficient mice. J Exp Med (2003) 1.02
Validation data for periprosthetic bone remodelling theories. J Biomech (2002) 1.02
BOB.1/OBF.1 deficiency affects marginal-zone B-cell compartment. Mol Cell Biol (2002) 1.01
Challenges in monoclonal antibody-based therapies. Ann Med (2009) 1.00
Hypervalent iodine goes catalytic. Angew Chem Int Ed Engl (2006) 1.00
Repressing the repressor: a new mode of MYC action in lymphomagenesis. Cell Cycle (2009) 1.00
Iodine electrophiles in stereoselective reactions: recent developments and synthetic applications. Chem Soc Rev (2004) 0.99
Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma. Curr Gene Ther (2009) 0.99
Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity. Eur J Pharm Biopharm (2008) 0.99
Cellular immune reaction in the pancreas is induced by constitutively active IkappaB kinase-2. Gut (2006) 0.98
Exact focusing of extracorporeal shock wave therapy for calcifying tendinopathy. Clin Orthop Relat Res (2002) 0.96
Highly stereoselective metal-free oxyaminations using chiral hypervalent iodine reagents. Angew Chem Int Ed Engl (2012) 0.94
Improving safety of gene therapy. Curr Drug Saf (2008) 0.94
Epithelial-mesenchymal transition in pancreatic carcinoma. Cancers (Basel) (2010) 0.94
Epstein-barr virus-induced gene-3 is expressed in human atheroma plaques. Am J Pathol (2009) 0.93
Controlling hazardous chemicals in microreactors: synthesis with iodine azide. Beilstein J Org Chem (2009) 0.92
Determination of hip reduction in spica cast treatment for DDH: a comparison of radiography and ultrasound. J Child Orthop (2009) 0.92
Selenium-containing naphthalimides as anticancer agents: design, synthesis and bioactivity. Bioorg Med Chem (2012) 0.92
Long-term IKK2/NF-κB signaling in pancreatic β-cells induces immune-mediated diabetes. Diabetes (2013) 0.90
Radiological determination of the anatomic hip centre from pelvic landmarks. Acta Orthop Belg (2010) 0.89
Stereoselective rearrangements with chiral hypervalent iodine reagents. Angew Chem Int Ed Engl (2013) 0.88
Myc regulates embryonic vascular permeability and remodeling. Circ Res (2009) 0.88
Activation of the IkappaB kinase complex is sufficient for neuronal differentiation of PC12 cells. J Neurochem (2005) 0.88
In vivo implantation of 2,2'-bis(oxazoline)-linked poly-epsilon-caprolactone: proof for enzyme sensitive surface erosion and biocompatibility. Eur J Pharm Sci (2008) 0.88
Sustained, neuron-specific IKK/NF-κB activation generates a selective neuroinflammatory response promoting local neurodegeneration with aging. Mol Neurodegener (2013) 0.88
Nonunion of forearm shaft fractures in children after intramedullary nailing. J Pediatr Orthop B (2009) 0.87
CD22 regulates early B cell development in BOB.1/OBF.1-deficient mice. Eur J Immunol (2002) 0.87
Caspase-mediated cleavage converts the tumor necrosis factor (TNF) receptor-associated factor (TRAF)-1 from a selective modulator of TNF receptor signaling to a general inhibitor of NF-kappaB activation. J Biol Chem (2003) 0.87
Tetrafluoro-IBA and-IBX: hypervalent iodine reagents. Angew Chem Int Ed Engl (2007) 0.86
Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. Int J Cancer (2007) 0.86
A practical microreactor for electrochemistry in flow. Beilstein J Org Chem (2011) 0.86
Flexible stereoselective functionalizations of ketones through umpolung with hypervalent iodine reagents. Angew Chem Int Ed Engl (2014) 0.86
Nuclear factor κB activation impairs ependymal ciliogenesis and links neuroinflammation to hydrocephalus formation. J Neurosci (2012) 0.86
Precision of preoperative digital templating in total hip arthroplasty. Acta Orthop Belg (2011) 0.86
Diazo compounds in continuous-flow technology. ChemSusChem (2014) 0.85
Neuronal cell death induced by antidepressants: lack of correlation with Egr-1, NF-kappa B and extracellular signal-regulated protein kinase activation. Biochem Pharmacol (2002) 0.85
Hypervalent iodine-catalyzed oxidative functionalizations including stereoselective reactions. Chem Asian J (2014) 0.85
Hypervalent iodine-mediated aziridination of alkenes: mechanistic insights and requirements for catalysis. Chemistry (2007) 0.85
Decitabine represses translocated MYC oncogene in Burkitt lymphoma. J Pathol (2013) 0.85
Selenocyclizations: control by coordination and by the counterion. Angew Chem Int Ed Engl (2004) 0.85
A multipurpose vector system for the screening of libraries in bacteria, insect and mammalian cells and expression in vivo. Nucleic Acids Res (2005) 0.85
B cell hyperresponsiveness and expansion of mature follicular B cells but not of marginal zone B cells in NFATc2/c3 double-deficient mice. J Immunol (2005) 0.85
Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma. PLoS One (2012) 0.85
Octamer-dependent transcription in T cells is mediated by NFAT and NF-κB. Nucleic Acids Res (2013) 0.85
Novel lactonization with phenonium ion participation induced by hypervalent iodine reagents. Org Lett (2003) 0.84
TKA following high tibial osteotomy versus primary TKA--a matched pair analysis. BMC Musculoskelet Disord (2010) 0.84
Malignant fibrous histiocytoma of the distal femur after an arthroscopic anterior cruciate ligament reconstruction: A case report and a review of the literature. BMC Cancer (2010) 0.84
Critical role of RelB serine 368 for dimerization and p100 stabilization. J Biol Chem (2003) 0.84
Expression of the aldehyde dehydrogenase 2-like gene is controlled by BOB.1/OBF.1 in B lymphocytes. J Biol Chem (2003) 0.84
Doxycycline regulation in a single retroviral vector by an autoregulatory loop facilitates controlled gene expression in liver cells. Nucleic Acids Res (2004) 0.84
MR imaging of lung parenchyma at 0.2 T: evaluation of imaging techniques, comparative study with chest radiography and interobserver analysis. Eur Radiol (2004) 0.83
15-Lipoxygenase-1 induces lipid peroxidation and apoptosis, and improves survival in rat malignant glioma. In Vivo (2012) 0.83
Btk expression is controlled by Oct and BOB.1/OBF.1. Nucleic Acids Res (2006) 0.83
Volumetric measurement of periprosthetic bone remodeling: prospective 5 years follow-up after cemented total hip arthroplasty. Arch Orthop Trauma Surg (2007) 0.83
Femoral strain changes after total hip arthroplasty--patient-specific finite element analyses 12 years after operation. Med Eng Phys (2005) 0.83
Reconstruction of the acetabulum in THA using femoral head autografts in developmental dysplasia of the hip. J Orthop Surg Res (2011) 0.82